MARKET

RMTI

RMTI

Rockwell Med Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.690
+0.020
+1.20%
Opening 13:33 05/24 EDT
OPEN
1.660
PREV CLOSE
1.670
HIGH
1.730
LOW
1.650
VOLUME
35.93K
TURNOVER
40.67K
52 WEEK HIGH
11.66
52 WEEK LOW
1.620
MARKET CAP
14.44M
P/E (TTM)
-4.8886
1D
5D
1M
3M
1Y
5Y
Rockwell Medical, Inc. to Present at H.C. Wainwright Annual Global Life Sciences Conference
Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the "Company"), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that Russell Ellison, M.D., M.Sc., President and Chie...
PR Newswire · 1d ago
20 Stocks Moving in Wednesday's Pre-Market Session
Gainers Decisionpoint Systems, Inc. (NASDAQ: DPSI) rose 47.2% to $7.02 in pre-market trading after jumping around 19% on Tuesday. DecisionPoint Systems recently reported first-quarter FY22 revenue growth of 22.7% year-on-year to $19.7 million.
Benzinga · 6d ago
Recap: Rockwell Medical Q1 Earnings
Rockwell Medical (NASDAQ:RMTI) reported its Q1 earnings results on Monday, May 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 05/16 21:42
Rockwell Medical Q1 EPS $(0.84) Up From $(0.91) YoY, Sales $16.12M Miss $17.65M Estimate
Rockwell Medical (NASDAQ:RMTI) reported quarterly losses of $(0.84) per share. This is a 7.69 percent increase over losses of $(0.91) per share from the same period last year. The company reported quarterly sales of
Benzinga · 05/16 20:23
Rockwell Medical GAAP EPS of -$0.84 beats by $0.15, revenue of $16.12M misses by $1.53M
Rockwell Medical press release (NASDAQ:RMTI): Q1 GAAP EPS of -$0.84 beats by $0.15. Revenue of $16.12M (+4.2% Y/Y) misses by $1.53M. As of March 31, 2022, cash and cash equivalents
Seekingalpha · 05/16 20:06
BRIEF-Rockwell Medical Reports Q1 Sales Rose 4.2% To $16.1 Million
reuters.com · 05/16 20:03
-- Earnings Flash (RMTI) ROCKWELL MEDICAL TECHNOLOGIES Posts Q1 Revenue $16.1M
MT Newswires · 05/16 16:05
Earnings Scheduled For May 16, 2022
  Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Benzinga · 05/16 09:18
More
No Data
Learn about the latest financial forecast of RMTI. Analyze the recent business situations of Rockwell Med Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RMTI stock price target is 44.00 with a high estimate of 55.00 and a low estimate of 33.00.
High55.00
Average44.00
Low33.00
Current 1.630
EPS
Actual
Estimate
-0.67-0.50-0.34-0.17
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 108
Institutional Holdings: 5.85M
% Owned: 68.48%
Shares Outstanding: 8.54M
TypeInstitutionsShares
Increased
15
147.72K
New
7
12.18K
Decreased
12
77.91K
Sold Out
11
31.10K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.05%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Non-Executive Chairman/Independent Director
John Mclaughlin
President/Chief Executive Officer/Director
Russell Ellison
Chief Financial Officer/Executive Vice President
Russell Skibsted
Chief Accounting Officer/Vice President/Controller
Paul McGarry
Vice President - Operations
Michael DeYoung
Other
Marc Hoffman
Other
Raymond Pratt
Independent Director
John Cooper
Independent Director
Allen Nissenson
Independent Director
Robert Radie
Independent Director
Mark Ravich
Independent Director
Andrea Smiley
No Data
No Data
About RMTI
Rockwell Medical, Inc. is a commercial-stage, biopharmaceutical company. The Company is developing and commercializing its technology platform, Ferric Pyrophosphate Citrate (FPC) for the transformative treatments for iron deficiency in multiple disease states. It is also a supplier of hemodialysis concentrate products to kidney dialysis clinics. The Company has developed therapies namely Triferic and Triferic AVNU from its FPC platform. The Company’s products from its FPC platform, Triferic (dialysate) and Triferic AVNU intravenous (IV), is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients. Its Triferic AVNU, is an IV formulation of Triferic, for use by hemodialysis patients. its dialysis concentrates products include CitraPure Citric Acid Concentrate, Dri-Sate Dry Acid Concentrate, RenalPure Liquid Acid Concentrate, Dry Acid Concentrate Mixer, RenalPure and SteriLyte Bicarbonate Concentrate and Ancillary products.

Webull offers kinds of Rockwell Medical Inc stock information, including NASDAQ:RMTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RMTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RMTI stock methods without spending real money on the virtual paper trading platform.